Harvard Bioscience Inc. (HBIO) - Company Projected Revenue

Harvard Bioscience (HBIO) partially relies on external component suppliers, focusing on final high-precision assembly. Projected sales revenue demonstrates a trend in inflows, where the current status is 0.09. Revenue stability is ensured by consistent demand for equipment from universities. Meanwhile, moderate pricing power is limited by budget cuts among US biotech startups, which constrains the growth of instrument costs.

Harvard Bioscience - HBIO Projected Sales Volume (period 07/04/2022 - 11/13/2026)

Summary analytical data breakdowns for Harvard Bioscience Inc. (HBIO)

- current price and projected stock value:

Stock Quotes Harvard Bioscience, Inc.|HBIO - Analyst Forecast Prices

- market capitalization indicators:

Market Value Harvard Bioscience Inc.|HBIO - Value Adjusted for Debt and Cash

- balance sheet equity data:

Accounting Value per Share Harvard Bioscience|HBIO - Book Capitalization|Market Value to Book Value Ratio harvardbioscience.com|HBIO - Cumulative Company Assets

- debt burden and liquidity indicators:

- financial results and valuation multiples details:

HBIO - Final Profit|Projected Future Earnings Harvard Bioscience|HBIO - P/E Multiple|Future Price to Earnings Harvard Bioscience, Inc.|HBIO - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Harvard Bioscience Inc.|HBIO - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Harvard Bioscience|HBIO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months harvardbioscience.com|HBIO - Earnings per share increase in current year|Earnings growth forecast for next year Harvard Bioscience

- sales volume and revenue indicators:

HBIO - Company Sales Volume|Company Future Sales Volume Harvard Bioscience|HBIO - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Harvard Bioscience Inc.

Summary company analytics:Harvard Bioscience, Inc. HBIO

The f_sales_co metric serves as a leading indicator of fundamental stability, assessing the expected revenue of the company. The calculation is based on the daily aggregation of market expectations, which eliminates the time lag associated with standard financial reporting. Analyzing the organization's prospective sales allows for the timely detection of shifts in long-term trends. For Harvard Bioscience (HBIO), the metric's dynamics reflect the efficiency of outsourcing production and services to third-party contractors. This enables investors to evaluate the scalability of the business model through the lens of future cash flows.

Key competitors